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Despite the many advances in the diagnosis and treatment of
ovarian cancer over the past four decades, this malignancy remains
the second most commonly diagnosed gynaecological cancer,
claiming more lives than any other tumour of the reproductive
system. One of the major challenges in treating women with
ovarian cancer is that diagnosis is usually made when the disease
has spread beyond the ovary. Although surgery is still considered
the first-line intervention, the majority of patients present too late
for curative removal of the tumour to be successfully achieved.
Hence, chemotherapy remains a key part of treatment for most
women with ovarian cancer.
This supplement brings together the views of several expert
groups, focusing on potential ways to improve the outcome of
treatment with chemotherapy.
Drs McGuire and Markman provide a thorough background and
summary of current standards of care. They describe the evolution
of treatment from initial single alkylating agents to current first-
line therapy comprising the taxane–platinum combination. They
recognise that there remains much scope for improvement. For
instance, the counterintuitive and controversial results of the
GOG-132 and OV010 trials (both of which indicate that the
taxane–platinum combination and single-agent platinum produce
equivalent results) have led to a number of new trial designs. In
particular, they have encouraged investigators to consider
sequential regimens, obviating the possibility of any negative
interaction between the two major drug classes. Results of these
various trials are awaited with interest. McGuire and Markman
also review a number of novel agents for the treatment of advanced
ovarian cancer, and this is certainly a very productive area. It is
worth pointing out that the current best treatment of patients with
optimally debulked disease typically leads to a median progres-
sion-free survival of approximately 18–20 months, and an overall
median survival approaching 48 months. In other words many
patients can expect to survive for more than 2 years beyond first
relapse. This points to the very large potential for benefit from
treatment for relapsed disease. Recent results from ICON-4
(Parmar et al, 2003) indicate the value of combination chemother-
apy over single-agent carboplatin in this context and highlights the
scope for the introduction of a range of new drugs. It also provides
an ideal opportunity for the use of the alternative taxane,
docetaxel, which is described in detail in the other articles.
Dr Katsumata provides a comprehensive review of the current
data on the use of docetaxel in ovarian cancer. Many clinicians
treating breast cancer have concluded that docetaxel is a superior
agent to paclitaxel, and a recently reported randomised trial in this
disease supports that view (Ravdin et al, 2003).
In ovarian cancer, preclinical data have indicated a lack of
complete crossresistance and the activity of docetaxel in paclitaxel-
refractory ovarian cancer (Verschraegen et al, 2000) is an
important observation, not least in support of the proposal that
it should be considered as a logical choice whenever retreatment
with a taxane is being considered. Numerous studies have
delineated the activity of docetaxel in combination with platinum
as well as in single-agent trials. The most extensive is the
randomised trial The Scottish Randomised Trial in Ovarian
Cancer that demonstrated equivalence in terms of efficacy between
paclitaxelcarboplatin and docetaxelcarboplatin in over 1000
patients. A key feature, however, was the significant difference in
neurotoxicity between the two schedules and this is emphasised by
several authors in this supplement. Katsumata also notes the added
convenience of the 1-h schedule of docetaxel, and it is important to
highlight that this offers patients the option of scalp-cooling to
prevent alopecia, a manoeuvre which in the majority of cases is
effective and worthwhile.
Drs Guastalla and Dieras pursue this discussion on the
differences in quality of life to be anticipated from paclitaxel-
and docetaxel-containing treatment in ovarian cancer. They point
out that while neutropenia is more pronounced with docetaxel,
this does not lead to a significant compromise in patient safety.
Quality of life is an important component of all clinical trials in
this disease and these authors highlight the progress being made in
developing reproducible tools for its assessment.
Dr Maenpaa focuses on the most recent developments in the use
of docetaxel in ovarian cancer. These include novel combinations
incorporating agents such as irinotecan, topotecan, gemcitabine,
vinorelbine and anthracyclines into docetaxel-containing regi-
mens. A range of promising second-line doublets has been
identified. Concurrent three-drug regimens provide more of a
challenge because of additive toxicity and this provides the
opportunity to explore sequential regimens, which are also
discussed by other authors.
Finally, Dr Vasey provides a timely reminder that the main
obstacle to further progress in chemotherapy in ovarian cancer is
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thorough understanding of the underlying mechanisms is still
required. This will require a concerted effort to collect appropriate
tissue from treated patients, so that mechanisms relevant to the
clinic rather than those described in experimental cell lines can be
identified. The current availability of microarray technology to
conduct comprehensive gene expression analyses offers much
hope for the future.
At present, however, clinicians will continue to pursue various
strategies aimed at overcoming resistance, and Dr Vasey describes
several of these. They include, as discussed previously, the
introduction of sequential regimens, in addition to dose-intense
or intraperitoneal administration of conventional drugs. Clearly,
toxicity issues will be as important as the demonstration of any
improvements in efficacy, and this is particularly relevant for the
intraperitoneal chemotherapy trials. Novel noncytotoxic agents
also represent an important element; aberrations in cell signalling
can lead to the failure of cells to undergo apoptosis and to drug
resistance; a range of novel drugs are capable of reversing this —
at least in experimental models.
In summary, there is now real potential for progress in the
treatment of ovarian cancer and this supplement provides a
number of examples of how this may be achieved.
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